Mar 10, 2022 07:10 AM

BUSINESS

China Meheco Links Up With Pfizer to Market Covid Pill

By Cui Xiaotian and Han Wei

China’s National Medical Products Administration (NMPA) granted conditional approval for Paxlovid Feb. 11

China’s National Medical Products Administration (NMPA) granted conditional approval for Paxlovid Feb. 11

China Meheco Corp. (600056.SH) secured a partnership with Pfizer Inc. to bring the American pharmaceutical giant’s new Covid-19 pill to the Chinese mainland, the state-owned drug maker said Wednesday.

Meheco said it signed a 2022 supply contract with Pfizer authorizing the Chinese company to commercialize Paxlovid in China. The agreement details delivery, payments, quality guarantee and assessment, contract termination and dispute resolution involving the partnership.

You've accessed an article available only to subscribers

Subscribe today for just $.99.

VIEW OPTIONS

Share this article

Open WeChat and scan the QR code

GALLERY

: Gallery: Putin’s Surprise Visit to Ukraine

NEWSLETTERS

Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription

PODCAST

China Stories: What Li Yining Taught China About Economic Reform

00:00

00:00/00:00

MOST POPULAR

1: Gallery: Nobel-Winning Japanese Author Dies

2: China Cuts Reserve Requirement Ratio To Boost Economy

3: China Cosco Unit Takes 25% Stake in New Egyptian Container Port

4: Tech Insider: U.K. Bans TikTok on Government Phones, Baidu Unveils China’s Answer to ChatGPT

5: China’s Bond-Feed Turmoil Triggered by Data Monopoly, Compliance Concerns, Sources Say

SPONSORED

OR